This has prompted plenty of coverage from the team at The Motley Fool about where investors should be scooping up value shares.

In addition to plenty of shares that may have been oversold during March, there are also ASX stocks that ignored broader market negativity and powered ahead. 

Let's look at three that have flown higher in 2026 despite broader volatility.

4DMedical Ltd (ASX: 4DX)

For those who missed it, 4DX Medical was one of the best ASX stocks to own in 2025. 

It is a medical technology company working in the field of respiratory imaging and ventilation analysis in the treatment of lung and respiratory diseases.

The company's non-invasive lung imaging technology emanates from research work undertaken at Monash University. 

It is the first FDA-cleared respiratory imaging solution that uses mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data.

In the last 12 months, this ASX stock has risen 2,000%. 

Yes, you read that right. 

While this rapid pace has slowed, it has still enjoyed a 39% rise year to date. 

For context, the S&P/ASX 200 Index (ASX: XJO) is up just 2.8% in the same period. 

So, where to now for this ASX stock?

Many holders would be considering profit-taking, while those on the outside looking in might have missed the boat. 

The Motley Fool's Samantha Menzies dove into this question recently, pointing out the gamble that some investors might be taking. 

It's possible this runaway train is now rising more on hype and hope rather than concrete earnings. 

Analysts forecasts via TradingView indicate it is now above fair value by approximately 34%. 

PLS Group Ltd (ASX: PLS)

PLS is an Australian lithium-tantalum producer positioning itself at the forefront of the rapidly growing global lithium industry.

While it hasn't been all smooth sailing, PLS shares are up 25% year to date and 283% in the last 12 months. 

Global lithium prices have been driving this growth, along with its dominant market position here in Australia. 

These drivers could continue to benefit this ASX 200 stock in the long term. 

However, 17 analyst forecasts via TradingView indicate that right now, it is trading close to fair value. 

Resolute Mining Ltd (ASX: RSG)

Resolute Mining is an Australia-based gold producer.

Like most gold stocks, it rallied throughout 2025. 

But while many other companies in the sector have fallen this year, Resolute Mining shares have continued to climb a further 17% in 2026. 

Unlike the previous ASX stocks mentioned, experts think Resolute Mining shares can continue to climb. 

7 analysts via TradingView have an average one-year price target of $2.13. 

This suggests a potential upside of 47% from current levels. 

The post Will these top-performing ASX stocks keep charging higher? appeared first on The Motley Fool Australia.

This uplift means the shares are now 32% higher for the year to date and up an enormous 2,208% over the past 12 months.

The healthcare technology company's shares have enjoyed an incredible run, but now I'm concerned that investors who are chasing the shares higher and higher could be taking a big gamble.

Why do 4DX shares keep soaring?

4DX is an ASX healthcare technology company that develops imaging software for healthcare providers to analyse airflow through the lungs. It helps identify and treat lung and respiratory diseases ranging from asthma to lung cancer.

The company saw its share price explode in 2025 after its flagship product, CT:VQ, received regulatory approvals. It was quickly implemented and adopted through partnerships and commercial contracts with healthcare organisations.

The company has already signed contracts with hospitals and medical providers across the US. These include Stanford University, the University of Miami, Cleveland Clinic, and UC San Diego Health.

It's this business shift from a research and development business to a globally commercial business that has attracted interest from investors.

Here's why it feels like a gamble

I'm concerned that after such a strong price rally over the past 12 months, the 4DX share price could begin to run away.

While a lot of the price increase is driven by company development and contract wins, it is also being driven by investor expectations and sentiment.

It's worth remembering that 4DX is still in a loss‑making, growth and commercialisation phase, which means the company is not yet a profitable business.

For the half year ended 31st December, 4DMedical reported a revenue of $2.9 million, but an adjusted net loss of $16.2 billion, meaning it is far from making money.

This means it also doesn't pay any dividends to its shareholders.

These types of companies often attract momentum and speculative trading and price increases feed more price increase. Essentially, investor optimism can drive gains.

The problem is that if developments or results don't live up to expectations, the share price can tumble just as quickly. 

This isn't to say that could happen. But to assume that it won't, or that it'll continue at the same rate, is a gamble I won't be taking.

The post Are investors taking a big gamble chasing 4DX shares higher and higher? appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are dropping:

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is down 2.5% to $5.50. Once again, this appears to have been driven by profit-taking from some investors. Investors have been bidding this respiratory imaging technology company's shares higher this month after it made a big announcement. 4DMedical advised that its CT:VQ technology has been deployed at the Mayo Clinic in the United States. The company's managing director and CEO, Andreas Fouras, was very pleased with the news. He said: "Mayo's deployment is uniquely significant. When the world's number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ." 4DMedical shares remain up approximately 30% since this time last month.

New Hope Corporation Ltd (ASX: NHC)

The New Hope share price is down 5% to $5.81. This has been driven by the coal miner's shares going ex-dividend on Tuesday. New Hope recently released its half-year results and declared a fully franked interim dividend of 10 cents per share. Eligible shareholders can now look forward to receiving this next month on 20 April.

Santos Ltd (ASX: STO)

The Santos share price is down 1.5% to $7.94. This may be due to reports that Donald Trump is intent on ending the US-Iran war sooner rather than later. Traders may believe that this could mean oil prices will pull back from recent highs.

St George Mining Ltd (ASX: SGQ)

The St George Mining share price is down over 4% to 11 cents. This is despite the rare earths company announcing a memorandum of understanding with Tecnicas Reunidas. The two parties will work to complete processing test work on samples of the rare earths resource at the Araxa niobium-REE Project in Minas Gerais, Brazil. St George Mining's executive chairman, John Prineas, commented: "We are very excited to be working with Tecnicas Reunidas to further assess the optimal processing route for the Araxa rare earths and to potentially access the vast European market for rare earths."

The post Why 4DMedical, New Hope, Santos, and St George Mining shares are dropping today appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is down 10% to $5.63. This may have been driven by profit-taking from some investors following a very strong gain last week. Investors were buying the respiratory imaging technology company's shares after it made a big announcement. 4DMedical revealed that its CT:VQ technology has been deployed at the Mayo Clinic in the United States. The company's managing director and CEO, Andreas Fouras, commented: "Mayo's deployment is uniquely significant. When the world's number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ."

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 3.5% to 14 cents. Although this semiconductor company announced a licensing agreement today, the market doesn't appear overly impressed given the customer and the terms. BrainChip has entered into a technology licensing deal with Korea-based semiconductor company EDGEAI for its Akida 2 neuromorphic IP. The company will receive unspecified payments as it provides various deliverables, including IP access, engineering support, and integration services, as well as royalties on product sales. The agreement is global and non-exclusive, meaning EDGEAI is not restricted from working with other technology providers. In addition, it can be terminated by the customer without cause on one month's notice.

Catapult Sports Ltd (ASX: CAT)

The Catapult Sports share price is down 14% to $2.92. This follows the release of the sports technology company's analyst day presentation. Catapult revealed bold growth ambitions, targeting a rise in average annual contract value (ACV) per pro team from US$20,000 to between US$100,000 and US$150,000. However, this will depend on successful upselling to existing teams and launching additional products.

Star Entertainment Group Ltd (ASX: SGR)

The Star Entertainment share price is down 2% to 12.25 cents. This morning, this casino and resorts operator revealed that it has entered into a binding commitment letter with funds associated with WhiteHawk Capital Partners. This is in relation to a refinancing of its debt. It notes that the annual interest rate based on the term SOFR plus a margin that is materially consistent with its recent facility agreements.

The post Why 4DMedical, Brainchip, Catapult, and Star Entertainment shares are falling today appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is up 3% to $6.47. This morning, the respiratory imaging technology company revealed that its CT:VQ product has received CE Mark certification for commercial use in the European Union. The company notes that this allows it to immediately commence commercial engagement with healthcare providers, which sets up a pathway for clinical adoption and collaboration with major European hospital networks. 4DMedical's CEO and founder, Andreas Fouras, said: "CE Mark certification for CT:VQ is a significant milestone that opens access to one of the world's largest and most sophisticated healthcare markets. Combined with FDA clearance, 4DMedical now holds regulatory approval to rapidly commercialise CT:VQ across both the U.S. and the EU."

Clinuvel Pharmaceuticals Ltd (ASX: CUV)

The Clinuvel Pharmaceuticals share price is up 1.5% to $9.93. This has been driven by news that the biopharmaceutical company is showcasing at America's largest dermatology conference. Clinuvel's head of North American operations, Dr Linda Teng, said: "Following the success of the 2025 AAD Meeting, our team has refined its approach to ensure maximum engagement with the dermatology community ultimately aimed at helping to treat patients with melanocortin therapies. We know there is great demand from physicians who wish to offer more to their vitiligo patients, while interest in our commercial program for EPP continues to grow as patients seek approved therapy."

Life360 Inc (ASX: 360)

The Life360 share price is up 1.5% to $19.28. This week, Bell Potter put a buy rating and $37.75 price target on its shares. This is almost double its current share price. Commenting on its expectations for the first quarter, the broker said: "After setting expectations relatively low for Q1, there is some chance of a small beat, perhaps more in the adjusted EBITDA margin rather than MAU growth."

Silex Systems Ltd (ASX: SLX)

The Silex Systems share price is up 1% to $5.34. This morning, the laser uranium enrichment technology company advised that Global Laser Enrichment (GLE) has received preliminary approval for a major US government funding package. GLE is the exclusive licensee of the Silex uranium enrichment technology. The performance-based incentives package will provide up to US$98.9 million (A$142.6 million) in tax and other economic incentives.

The post Why 4DMedical, Clinuvel, Life360, and Silex shares are pushing higher today appeared first on The Motley Fool Australia.

Again.

Shares in the S&P/ASX 300 Index (ASX: XKO) respiratory imaging technology company closed yesterday trading for $6.28. In earlier trade, shares leapt to $7.55, up 20.2%. After some likely profit-taking, in later morning trade, shares are changing hands for $6.85 apiece, up 9.1%.

For some context, the ASX 300 is down 0.3% at this same time.

Taking a step back, the 4DMedical share price is now up a jaw-dropping 2,074.6% over 12 months. That meteoric rise has been spurred by a series of international regulatory approvals for its CAT scan-based ventilation-perfusion software, CT:VQ.

Indeed, just one year ago, you could have bought the ASX 300 healthcare stock for a mere 31.5 cents. That would have turned an $8,000 investment into $173,968.

Boom!

Now, here's what's catching investor interest again today.

4DMedical share price surges on EU approval

The 4DMedical share price is leaping higher after the company announced that CT:VQ has received CE Mark certification for commercial use in the European Union.

The company noted that CE Mark certification enables it to immediately commence commercial engagement with healthcare providers across the EU. This sets up a pathway for clinical adoption and collaboration with major European hospital networks.

Investors will also have noted that the EU has a population of more than 450 million. And with the economic block already home to highly developed hospital-based imaging infrastructure, 4DMedical said the EU constitutes one of the largest global markets for advanced cardiothoracic imaging.

What else is impacting the 4DMedical share price today?

Atop the European Union's CE Mark certification, the company also announced an institutional capital raising.

4DMedical said it has received commitments from institutional investors for an $83 million private placement at an issue price of $5.90 per share.

That's a 6.1% discount to the 4DMedical share price at market close yesterday. But the company noted it represents a 12.3% premium to the 5-day volume average weighted price (VWAP).

The proceeds will be used, in part, to fund the commercial launch of CT:VQ across Europe and international markets.

What did management say?

Commenting on the EU green light and capital raise that sees the 4DMedical share price up sharply again today, CEO and founder Andreas Fouras said, "CE Mark certification for CT:VQ is a significant milestone that opens access to one of the world's largest and most sophisticated healthcare markets."

Fouras continued:

Combined with FDA clearance, 4DMedical now holds regulatory approval to rapidly commercialise CT:VQ across both the US and the EU. Since FDA clearance, rapid adoption by leading US institutions … reflects the level of excitement CT:VQ is generating in the United States.

This placement, timed alongside CE Mark certification, gives us the resources to carry that same momentum into Europe… With an estimated 400,000 nuclear VQ scans performed annually across the EU, and an extensive network of CT scanners, the European opportunity is substantial and immediate.

The post Up 2,075% in a year, why is the 4DMedical share price rocketing again on Friday? appeared first on The Motley Fool Australia.

The uptick means the shares have now rocketed 55% over the past week. They're now up a huge 71% over the past month and are 40% higher over the year to date.

Most impressively, 4DX shares are 1,890% higher than this time 12 months ago, driven by regulatory approvals and a portfolio of signed contracts with hospitals and medical providers.

The ASX healthcare technology company develops imaging software for healthcare providers to analyse airflow through the lungs. It helps identify and treat lung and respiratory diseases ranging from asthma to lung cancer.

The company saw its share price explode in 2025 after its flagship product, CT:VQ, received regulatory approvals. It was quickly implemented and adopted through partnerships and commercial contracts with healthcare organisations.

4DMedical has already signed contracts with hospitals and medical providers, primarily across the US. Stanford University, the University of Miami, Cleveland Clinic, and UC San Diego Health have all rolled out the technology at their centres.

So, why are 4DX shares in the spotlight this week?

4DX announced yesterday that its CT:VQ has now been deployed at the Mayo Clinic in the US for ventilation and perfusion analysis. 

The clinic is widely-regarded as one of the world's leading hospitals. This makes it a landmark moment for 4DX and its shares. 

The news comes amid the company's rapid repositioning from a research and development business trialling new technology, to a globally commercial business. And this has happened within a very short period of time.

Investors are clearly jumping on board and it is sending the share price flying.

What's next for 4DX in 2026?

Development and rapid adoption of the company's technology also mean 4DMedical has smashed its milestone goals this year. 

Approvals have been secured in Canada and New Zealand, and now the company is turning its attention to Europe and Australia.

What's the outlook for 4DX shares?

The latest share price surge even took analysts by surprise. Despite the majority of brokers holding strong buy ratings, the target prices all now imply a significant downside for 4DX shares from here. We may see analysts confirm or update their expectations for the shares in coming days.

What's clear though, is that the share price rally demonstrates high expectations for the outlook of the company's growth. I think we'll see plenty more from 4DX shares this year.

The post Why is everyone talking about 4DX shares this week? appeared first on The Motley Fool Australia.

Over the past year, defence stocks have grabbed the headlines with Droneshield Ltd up 330% and Electro Optic Systems Ltd (ASX: EOS) up 540% but the returns from 4DMedical, up a staggering 1,630%, are hard to ignore.

What is driving such an astronomical share price increase?

A major endorsement from Mayo Clinic

The catalyst for the latest move is the deployment of 4DMedical's CT:VQ technology at the Mayo Clinic in the United States, widely regarded as one of the best hospitals in the world.

This is a high credibility signal. When an institution like Mayo adopts a new technology, it carries weight across the broader healthcare system.

Mayo will use the technology for ventilation and perfusion analysis, initially integrating it into clinical workflows and evaluating its use across a range of applications.

Building serious momentum

What also stands out is the speed of adoption.

In just seven months since receiving FDA clearance in September 2025, 4DMedical has secured deployments at six leading US academic medical centres, including Stanford, Cleveland Clinic, and the University of Chicago.

That level of traction in such a short timeframe is unusual and suggests strong early demand.

The company's value proposition is clear. Its technology eliminates the need for radioisotopes and contrast agents, integrates into existing CT workflows, and delivers high resolution functional imaging.

It also aligns with reimbursement pathways, which is critical for real world adoption.

What investors should watch

There is no doubt that 4DMedical is one of the hottest stocks on the ASX right now. The rally reflects growing confidence that the company is moving beyond a promising technology story into early commercial execution.

With a market cap exceeding $3Billion, expectations are sky high and the next phase is strong execution. Investors will want to see these deployments translate into meaningful revenue and over time, free cash flow.

The post Forget DroneShield and EOS, this ASX healthcare stock is up 15x in a year! appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are racing higher:

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is up 34% to $6.21. Investors have been buying this respiratory imaging technology company's shares after it made a big announcement. 4DMedical revealed that its CT:VQ technology has been deployed at the Mayo Clinic in the United States. The company's managing director and CEO, Andreas Fouras, commented: "Mayo's deployment is uniquely significant. When the world's number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ."

Brazilian Rare Earths Ltd (ASX: BRE)

The Brazilian Rare Earths share price is up 8.5% to $4.44. This morning, this rare earths developer revealed that it has secured a Trial Mining Licence from Brazil's National Mining Agency for its Monte Alto project in Bahia. This allows for the extraction of up to 2,000 tonnes per annum of material from the deposit. The company's managing director and CEO, Bernardo da Veiga, said: "Securing the Trial Mining Licence is a significant milestone for Monte Alto and a major step forward in BRE's integrated ore-to-oxides development pathway in Brazil."

Clarity Pharmaceuticals Ltd (ASX: CU6)

The Clarity Pharmaceuticals share price is up 18% to $3.63. This has been driven by news that the radiopharmaceuticals company has signed a large-scale manufacturing agreement with US-based company Theragenics. This gives Clarity access to a 134,000 square foot production facility with 14 cyclotrons capable of producing copper 64 at scale. The company notes that copper 64 offers a key advantage over traditional isotopes. This is due to its longer half-life of around 12.7 hours, which provides a shelf life of up to 48 hours.

Tuas Ltd (ASX: TUA)

The Tuas share price is up 5.5% to $6.33. This morning, this Singapore-based telco released its half-year results for FY 2026. Tuas revealed a 25.5% increase in revenue to S$91.9 million and a 27.2% jump in underlying EBITDA to S$41.1 million. Management advised that this strong growth reflects sustained improvement across all key financial metrics, supported by disciplined cost management and operating leverage.

The post Why 4DMedical, Brazilian Rare Earths, Clarity, and Tuas shares are racing higher today appeared first on The Motley Fool Australia.

In early trade, the ASX 300 stock is up a massive 38% to a record-high of $6.40.

Why is this ASX 300 stock rising today?

Investors have been buying the respiratory imaging technology company's shares following the release of a big announcement this morning.

According to the release, 4DMedical's CT:VQ technology has been deployed at the Mayo Clinic in the United States.

The release reveals that the Mayo Clinic, which is widely regarded as one of the world's leading hospitals, has entered into an agreement to use CT:VQ for ventilation and perfusion analysis.

The deployment will initially focus on integrating the technology into clinical workflows and allowing clinicians to evaluate its capabilities across a range of use cases.

Management highlights that the Mayo Clinic's adoption represents one of the most significant endorsements of its technology to date.

Building strong commercial momentum

The ASX 300 stock notes that it has achieved six major deployments for CT:VQ within approximately seven months of receiving FDA clearance in September 2025.

The others are Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, and the University of Miami.

This rapid adoption highlights growing demand for its technology, which offers advantages such as eliminating the need for radioisotopes and contrast agents, while providing high-resolution imaging and integration into existing CT workflows.

While the initial agreement with Mayo Clinic is not financially material, the company emphasised its strategic importance. Management believes that as clinicians gain confidence in the technology, the hospital could become a key reference site, supporting broader commercial adoption.

'A landmark moment'

The ASX 300 stock's managing director and CEO, Andreas Fouras, described the deployment as a landmark moment for the company. He said:

Mayo Clinic is, unquestionably, one of the most respected healthcare institutions in the world. Their decision to deploy CT:VQ is a landmark moment for 4DMedical and a powerful testament to the clinical significance of our technology. In just seven months since FDA clearance we have established CT:VQ at six of America's leading AMCs: Stanford, University of Miami, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, and now Mayo Clinic. No other technology in our space has achieved this level of clinical adoption in such a short timeframe.

Mayo's deployment is uniquely significant. When the world's number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ.

Fouras believes this leaves the company well-placed for the future. He concludes:

Combined with our existing network of elite AMC reference sites, and the Philips partnership, we are building an unassailable platform for CT:VQ adoption. CT:VQ continues to accelerate. Our sales pipeline has never looked stronger, and I look forward to sharing further progress soon.

The post ASX 300 stock rockets 38% on 'landmark moment' appeared first on The Motley Fool Australia.

The decline might look concerning on the surface, but it has barely dented the company's gains over the past 12 months. At the time of writing, 4DMedical shares are trading an enormous 950% higher than this time last year.

What has happened to the ASX tech stock's shares?

4DMedical is a healthcare technology company that develops imaging software for healthcare providers to analyse airflow through the lungs. It helps identify and treat lung and respiratory diseases ranging from asthma to lung cancer.

The company saw its share price explode in 2025 after its flagship product, CT:VQ, received regulatory approvals. It was quickly implemented and adopted through partnerships and commercial contracts with healthcare organisations.

4DMedical has already signed contracts with hospitals and medical providers, primarily across the US. Stanford University, the University of Miami, Cleveland Clinic and UC San Diego Health have all rolled out the technology at their centres.

In short, 4DMedical moved from a research and development business trialling new technology, to a globally commercial business within a very short period of time.

There is no price-sensitive news out of the company to explain the softening share price in 2026. But after such an enormous price tally in 2025, it's likely that investors are taking their gains off the table.

What's next for the company in 2026?

Development and rapid adoption of the company's technology also mean 4DMedical has smashed its milestone goals. 

In 2026, 4DMedical will focus on accelerating the rollout of its newly FDA-approved CT:VQ imaging product through more strategic partnerships and new contracts. 

Approvals have been secured in Canada and New Zealand. The company is now actively progressing commercialisation plans in Europe and Australia.

This month, 4DMedical was also added to the All Ordinaries Index (ASX: XAO) and the S&P/ASX 300 Index (ASX: XKO).

Is it too late to buy the ASX tech stock, or is there more upside to come?

Despite the strong rally over the past year and the 2026 sell-off, most analysts remain very bullish on the stock's outlook.

TradingView data shows that two out of three analysts have a strong buy rating on the shares, while one has a strong sell stance on the stock.

The maximum target price is $4.90, implying another 27% upside for investors at the time of writing. 

The post Up over 900%: Is it too late to buy this incredible ASX tech stock? appeared first on The Motley Fool Australia.

Monday saw the biggest sell-off in almost a year, as investor sentiment was extremely defensive due to developing conflict in the Middle East. 

It felt as though this was the beginning of an extended decline, as many investors positioned themselves for a risk-off period. 

However before the market crash could even begin, it bounced back yesterday. 

The Motley Fool's Bernd Struben explained in detail yesterday the factors that are influencing this volatility.

While investors were able to breathe a momentary sigh of relief, there are likely more ups and downs to come. 

What happened to these shares yesterday?

The S&P/ASX 200 Index (ASX: XJO) finished Tuesday a full 1% higher than Monday. 

Two ASX shares that vastly outperformed the benchmark index were 4DMedical Ltd (ASX: 4DX) and Life360 Inc (ASX: 360). 

These stocks rose 9.11% and 10.34% respectively.

This came after crashes of 5% and 7% on Monday. 

What's more interesting, is these companies are part of two of Australia's worst performing ASX sectors this year: healthcare and technology.

Following this week's turbulence, 4DMedical shares are down 2.4% year to date, and up more than 1,000% in the last 12 months. 

Meanwhile, Life360 shares are down 30% year to date and down 2% over the last 12 months. 

With so much movement, it can be difficult for prospective investors to identify an attractive entry point. 

Here is the latest guidance from analysts. 

Life360 shares

For those unfamiliar, Life360's core product is a private family and friends social networking app that allows users to communicate and share their locations.

It was a strong performer across 2024-2025, however has been heavily sold off this year, most recently on the back of disappointing results.

It closed yesterday at $22.51. 

Based on guidance from brokers, it now looks like an attractive buy. 

Investors will be hoping it has finally hit rock bottom after a tough start to 2026. 

Bell Potter has a recent target of $40.00. 

Recently, Morgan Stanley put an overweight rating and $50.00 price target on Life360 shares. 

These targets indicate an upside in the range of 77% to 122%. 

Based on this guidance, it seems yesterday's spike could be the beginning of a recovery for Life360 shares. 

Can 4DMedical keep rising?

4DMedical has been one of the hottest ASX shares over the last year. 

It closed yesterday at $4.43 per share, an astounding 1,035.90% higher than 12 months ago. 

It is a medical technology company working in the field of respiratory imaging and ventilation analysis in the treatment of lung and respiratory diseases.

Despite yesterday's 9% rise, it seems analysts largely see the current share price as hovering close to fair value. 

Analysts forecasts via TradingView have an average one year price target of $4.20 on this ASX stock. 

That's approximately 5% lower than yesterday's price target. 

The post Are 4DMedical and Life360 shares a buy, hold or sell after rocketing 10% yesterday? appeared first on The Motley Fool Australia.

Australia's benchmark index swung heavily throughout the week, ultimately finishing 2.95% lower on Friday's close than Monday's open. 

Three ASX shares in particular that bounced around were: 

• Light & Wonder Inc (ASX: LNW)
• Domino's Pizza Enterprises Ltd (ASX: DMP)
• 4DMedical Ltd (ASX: 4DX)

When stocks crash and recover on a daily basis, it can be difficult for investors to pinpoint true value. 

Here's what experts are saying about these ASX shares. 

Light & Wonder

Light & Wonder shares crashed more than 7% at the start of last week. They then recovered by Thursday, before falling again on Friday. 

All in all, they finished the week down 1.35%. 

It's been a rough start to the year for the game developer, down 28% since the middle of January. 

Holders of this ASX 200 stock will be pleased to know that analysts have a positive outlook, meaning there is the possibility of a larger recovery. 

Last week, Morgans had a buy rating and $195 price target on the company. 

Unlike other sectors, the broker thinks AI disruption will strengthen its competitive edge. 

From Friday's closing price of $129.97, the Morgans price target indicates an upside of 50%. 

Elsewhere, Bell Potter is tipping even more upside for the ASX 200 stock. 

The broker has a $220 price target on Light and Wonder shares. 

Domino's Pizza Enterprises

It was also a turbulent week for Domino's shares. 

The ASX 200 stock initially dropped 12% before recovering significantly. 

It finished the week 3.74% lower than Monday's open. 

This is a snapshot of what Domino's shareholders have endured over the last year. 

The share price is ultimately down 29% for the last 12 months. 

Outlook is mixed amongst experts moving forward. 

Morgans currently has a buy rating and $25 price target on Domino's shares. 

Meanwhile, Morgan Stanley has a sell rating on Domino's Pizza shares with a target of just $15.20.

The ASX 200 company closed last week in between these targets at $19.07. 

4DMedical

This ASX stock was another up-and-down company last week. 

It endured heavy rises and falls but finished the week more than 13% above Monday's open. 

The medical technology company is up an astounding 1000% in the last year. 

Following such a run, there are now questions on valuation vs revenue. 

Meanwhile, Bell Potter is optimistic that the growth can continue. 

The broker set a $4.50 price target and issued a buy recommendation.  

That indicates an upside of roughly 4% from last week's close. 

The post What to make of these volatile ASX shares appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is up 7.5% to $4.00. Investors have been buying the respiratory imaging solutions provider's shares following the release of its half-year results. 4D Medical reported a 1% decline in revenue to $2.8 million and an adjusted net loss of $16.2 million. The latter was an improvement of 18% on the prior corresponding period. At the end of the period, the company had a pro forma cash position of $206.2 million. Looking ahead, the company highlights that its recently approved CT:VQ product has a major market opportunity. It said: "CT:VQ addresses a substantial market opportunity, with over one million nuclear VQ scans performed annually in the U.S. at an average reimbursement of approximately US$1,150 per scan, representing an initial addressable market exceeding US$1.1 billion annually in the U.S. alone (estimated at over US$2.6 billion globally)."

Block Inc (ASX: XYZ)

The Block share price is up 28% to $93.95. This has been driven by the release of the payments giant's full-year results and the announcement of major job cuts. For the 12 months ended 31 December, Block's gross profit increased 17% to US$10.36 billion. This reflects a 21% jump in Cash App gross profit to US$6.34 billion and a 9% lift in Square gross profit to US$3.94 billion. But the big news was Block's founder and CEO, Jack Dorsey, revealing a massive reduction in its workforce. He said: " Today we shared a difficult decision with our team. We're reducing Block by nearly half, from over 10,000 people to just under 6,000. […] The core thesis is simple. Intelligence tools have changed what it means to build and run a company. We're already seeing it internally. A significantly smaller team, using the tools we're building, can do more and do it better. And intelligence tool capabilities are compounding faster every week. I don't think we're early to this realization. I think most companies are late."

PEXA Group Ltd (ASX: PXA)

The PEXA share price is up 6.5% to $15.23. This morning, this property settlements technology company released its half-year results. It reported a 10% increase in revenue to $215.3 million and a 33% jump in group NPATA to $40.3 million. PEXA's CEO, Russell Cohen, said: "PEXA delivered a strong result in the first half in FY26, underpinned by record transaction volumes in Australia, disciplined cost management and continued progress in the UK."

Weebit Nano Ltd (ASX: WBT)

The Weebit Nano share price is up 3% to $4.88. This follows the release of the semiconductor company's half-year results. Weebit Nano reported record half-year revenue of $5.6 million. This means it is on track to achieve its full-year revenue guidance of $10 million. Weebit Nano's CEO, Coby Hanoch, said: "The first half of FY26 has marked Weebit's strongest start to a fiscal year in the company's 10-year history as technical and commercial momentum continues to build."

The post Why 4DMedical, Block, PEXA, and Weebit Nano shares are launching higher today appeared first on The Motley Fool Australia.

A good run of financial results and increased adoption of its technology, all while the company smashed its milestone goals throughout the year, sent the share price rocketing.

Most recently, 4DMedical announced that UC San Diego Health was the latest institution to adopt its flagship CT:VQ product. There has already been uptake by other centres, including Stanford University, the Cleveland Clinic, and the University of Miami.

Where is the 4DMedical share price now?

At the time of writing, the shares are 0.92% lower at $3.76 each. The drop means the shares are now 16.96% lower year to date and have fallen 26.18% from their all-time high of $5.09 in mid-January.

But it isn't all bad news. Since starting their speedy ascent in August last year, 4DMedical shares have rocketed 1,109.68% and they're now 583.64% above where they were just 12 months ago.

The question now is, what's next? Can the share price climb even higher, or is it time to sell up ahead of the next downturn?

Are 4DMedical shares a buy, hold, or sell this year?

Despite the strong rally over the past year and the sell-off this month, analysts remain very bullish on the stock's outlook.

Data shows that two out of three analysts have a strong buy rating on the shares, and the maximum target price is $4.50. That implies a potential 19.68% upside ahead for investors, at the time of writing. 

What's next from 4DMedical?

Late last month, the healthcare tech company posted its quarterly update and new commercial development. The announcement revealed that its CT:VQ product has moved beyond regulatory approval and into full commercial execution. The technology has now been adopted in five top-tier US academic centres within five months of FDA clearance.

At the same time, the company also revealed that its SaaS revenue grew 31% in the first half of FY26 and that its net operating cash outflows declined 21% in Q2 FY26. 

4DMedical ended the quarter with $56.8 million in cash, rising to a pro forma balance of $206.2 million following a $150 million institutional placement completed in January.

Management estimates the company has around 5.8 quarters of funding available, providing ample time to execute its US commercial strategy.

In 2026, 4DMedical will focus on accelerating the rollout of its newly FDA-approved CT:VQ imaging product through strategic partnerships and new contracts. 

The post 4DMedical shares jump 600% in a year: Time to sell up or can the stock go higher? appeared first on The Motley Fool Australia.

In morning trade, the health imaging technology company's shares are down almost 20% to $136.75.

This follows the release of the company's half-year results.

Pro Medicus shares crash on results day

For the six months ended 31 December, Pro Medicus reported a 28.4% increase in revenue to $124.8 million. This was underpinned by six key implementations in the half, all of which are cloud-based.

Pro Medicus' underlying EBIT margin increased to 73% from 72% a year earlier. This underpinned a 29.7% lift in underlying profit before tax to a record of $90.7 million.

Reported net profit after tax came in at $171.2 million, which is up 230.9% on the prior corresponding period. This reflects unrealised gains from its investment in 4DMedical Ltd (ASX: 4DX).

Commenting on the company's performance, CEO Dr Sam Hupert said:

Our profits continue to grow strongly even though our biggest implementation during the period in Trinity Cohort 1 went live towards the end of October so had limited impact on the half. Importantly, our margins also grew, and we made more sales in this half than we used to make in a full year just 2 years ago. Most contracts were for the full stack of Visage products – Viewer, Workflow and Archive and two also included our cardiology offering making them full stack +1, a trend we see continuing.

What about the AI threat?

In an accompanying interview, Dr Hupert spoke at length about the threat of AI on the company's business.

The good news is that he doesn't believe its Visage software is going to be replaced by AI. He explains:

The second concern is a belief held by some that new AI tools will radically disrupt software development with Vibe coding helping destroy the "IP moat" of all software and SaaS providers. They claim anyone will be able to use AI tools to write industry grade software in a fraction of the time.

This, in our view, is an overly simplistic generalisation, one that certainly doesn't apply to us. Visage 7 was built from the ground up using our own proprietary technology. It is not based on some readily available tool kit or platform. It is a very specialised, highly technical, patented suite of software that incorporates more than 30 years of domain knowledge; it is not a product that can be readily replicated with or without AI. We have not left a roadmap for others to follow.

The post Pro Medicus shares crash 20% on results day appeared first on The Motley Fool Australia.

Here, we canvas the views of two experts on three ASX All Ords shares within the consumer staples, utilities, and healthcare sectors.

One is a buy, one is a hold, and one is a sell.

Let's review.

Bubs Australia Ltd (ASX: BUB)

Bubs Australia shares are steady at 13 cents per share on Tuesday.

The share price of this milk producer has risen 8.3% over the past 12 months.

Shaw and Partners has a buy rating on the ASX consumer staples share.

Bubs released its 2Q FY26 quarterly activities report on 30 January.

The company reported 2Q FY26 net revenue of $29.9 million, up 17%, and 1H FY26 net revenue of $55.5 million, up 14.3%.

After reviewing the report, Shaw and Partners lowered its 12-month price forecast from 20 cents to 17 cents per share.

The broker said:

[The] 2Q FY26 quarterly activities report highlighted another strong quarter of sales in the USA, and ongoing inventory issues plus some challenging conditions in Australia, China, and ROW.

The company remains confident of receiving permanent FDA approval and noted the FDA has no further questions on the clinical trial component of its submission at this time.

Conditions in Australia/China/ROW should improve in 2H26.

We have adjusted our BUB forecasts to incorporate the 2H26 quarterly.

Given the expected TSR [total shareholder return] of circa 31%, we rate the stock a BUY. 

Origin Energy Ltd (ASX: ORG)

The Origin Energy share price is $11.01, down 1.1% today and up 8.8% over the past 12 months.

In a new note, Ord Minnett maintains a hold rating on this ASX utilities share.

The broker lifted its share price target from $10.80 to $11, implying the stock is fully valued today.

Ord Minnett said:

… we remain cautious on Origin given the headwinds we see – increased capital expenditure to maintain APLNG production, ongoing bad debt problems at Octopus, weaker wholesale electricity pricing, and a likely fall in spot LNG prices – and remain at Hold.

4DMedical Ltd (ASX: 4DX)

4DMedical shares are $3.45 apiece, down 0.4% today.

The respiratory imaging technology company has enjoyed a stunning share price growth of 562% over the past year.

On The Bull this week, Tony Paterno from Ord Minnett explained the broker's sell rating on the rocketing ASX healthcare share.

Paterno said:

In our view, there's a growing disconnect between 4DX's valuation and the uncertainty around near term CT:VQ revenue generation.

While we remain positive on 4DX's technology, we pull back to a sell recommendation on valuation grounds. 

The post Buy, hold, sell: Bubs, Origin Energy, 4D Medical shares appeared first on The Motley Fool Australia.

Listed below are two that experts are tipping as buys and one that they believe investors should be selling, courtesy of The Bull.

Here's what they are recommending:

4DMedical Ltd (ASX: 4DX)

The team at Ord Minnett thinks that respiratory imaging technology company 4DMedical is a small-cap ASX share to sell now.

However, this isn't due to a lack of quality. The recommendation is based on valuation grounds after a very strong rise over the past 12 months. It explains:

4DX enjoyed a positive start to calendar year 2026 after the company announced UC San Diego Health had adopted its CT:VQ product. Also, the company completed a $150 million institutional placement to primarily accelerate the commercialisation of CT:VQ. The share price has risen from 32 cents on June 2, 2025 to trade at $3.16 on February 5, 2026. In our view, there's a growing disconnect between 4DX's valuation and the uncertainty around near term CT:VQ revenue generation. While we remain positive on 4DX's technology, we pull back to a sell recommendation on valuation grounds.

Legacy Minerals Holdings Ltd (ASX: LGM)

Over at Alto Capital, analysts think this mineral exploration company is a buy.

It notes that the company is due to release its scoping study for Mt Carrington in the coming months, which could be a positive catalyst for its shares. Alto Capital said:

This exploration company focuses on gold, silver and base metals targets in New South Wales, with its flagship Mt Carrington project located in the Lachlan Fold Belt. Recent funding has strengthened the balance sheet and supports ongoing drilling across priority targets. The company is also expected to release a revised scoping study for Mt Carrington in March, providing a key near term catalyst. While early stage exploration carries inherent geological risk, any success at Mt Carrington would be significant given LGM's modest market capitalisation.

Praemium Ltd (ASX: PPS)

This investment platform provider's shares could be a buy according to analysts at Ord Minnett.

It has been pleased with its performance in FY 2026 and believes the trend can continue thanks to its improving outlook. Ord Minnett explains:

PPS provides an investment platform to enable financial advisers to manage client accounts. The company's second quarter update in fiscal year 2026 revealed some encouraging trends, even if progress was uneven across its products. Improving inflows to the Powerwrap platform was a highlight, while Praemium SMA was impacted by a client transition. Overall, net inflows were solid and platform funds under administration of $32.5 billion were up 8 per cent and in line with expectations. We still see an improving outlook for PPS.

The post Experts name 2 small-cap ASX shares to buy and one to sell appeared first on The Motley Fool Australia.

Shares in the respiratory imaging technology company closed on Friday trading for $3.10. In early afternoon trade on Monday, shares are changing hands for $3.34 apiece, up 7.7%.

For some context, the All Ordinaries Index (ASX: XAO) is up 2.0% at this same time.

Today's outperformance is par for the course for the medical technology stock in recent months.

Indeed, 4DMedical shares are now up an eye-popping 542.3% since this time last year.

That's enough to turn a $10,000 investment into $64,231. In one year.

Of course, those juicy gains have already been delivered.

Which brings us back to our headline question.

Should you buy 4DMedical shares today?

Ord Minnett's Tony Paterno recently ran his slide rule over the ASX medical tech stock (courtesy of The Bull).

"4DX is a respiratory imaging technology company," Paterno said.

He noted:

4DX enjoyed a positive start to calendar year 2026 after the company announced UC San Diego Health had adopted its CT:VQ product. Also, the company completed a $150 million institutional placement to primarily accelerate the commercialisation of CT:VQ.

CT:VQ, if you're unfamiliar, is the company's CAT scan-based ventilation-perfusion software.

But with 4DMedical shares having rocketed higher over the past six months, Paterno issued a sell recommendation on the stock.

According to Paterno:

The share price has risen from 32 cents on June 2, 2025 to trade at $3.16 on February 5, 2026. In our view, there's a growing disconnect between 4DX's valuation and the uncertainty around near-term CT:VQ revenue generation.

While we remain positive on 4DX's technology, we pull back to a sell recommendation on valuation grounds.

What's been happening with the ASX healthcare share?

The company released its December quarterly results on 30 January, highlighting that the three-month period saw CT:VQ move beyond regulatory approval and into full commercial execution.

4DMedical shares closed down 7.6% on the day, despite the company noting that CT:VQ is being used at a growing number of US health centres. Those include Stanford, the Cleveland Clinic, UC San Diego Health, the University of Miami, and the University of Chicago Medicine.

The company also reported that UChicago Medicine was also going to deploy CT:VQ.

4DMedical CEO and founder Andreas Fouras said:

University of Chicago Medicine is one of the nation's most respected AMCs and a pioneer in medical innovation. Their expansion of our partnership to include CT:VQ represents powerful validation of both the clinical value our technology delivers and the strength of our commercialisation approach.

4DMedical reported a pro forma cash balance of $206 million as at 31 December.

The post Up 542% in a year, is it too late to buy 4DMedical shares today? appeared first on The Motley Fool Australia.

In fact, the S&P/ASX 200 Health Care Index (ASX: XHJ) fell almost 25% in that span. 

Two exceptions to this broader fall were Artrya Ltd (ASX: AYA) and 4DMedical Ltd (ASX: 4DX).

These two ASX healthcare stocks have rocketed between 300% and 500% in the last year. 

However, both have dipped substantially in the last couple of weeks. 

They may now be priced at an attractive entry point relative to 52-week highs. 

Artrya

Artrya is an AI-driven medical technology company that assists clinicians in the diagnosis of coronary heart disease. 

Artrya's Salix Coronary Anatomy is a coronary computed tomography angiography (CCTA) image analysis solution that allows physicians with AI to identify and analyse the extent and type of arterial plaque, and help identify patients at risk of a heart attack.

A year ago, its share price was hovering around $0.83 per share. 

It hit an all-time high last week of more than $5 per share. 

However, the share price has retreated over the last week and now sits significantly below the all-time high at approximately $3.38. 

For prospective investors, all eyes will be on the company's expansion into the US market. 

On January 30, the ASX healthcare stock released its quarterly activities report.

In the report, John Konstantopoulos, Co-Founder and CEO of Artrya, commented:

This Quarter has been pivotal for Artrya as we continue to build momentum in the U.S. market. 

We achieved our first fee-per-scan revenues from the FDA-cleared Salix® Coronary Plaque module with Tanner Health, marking the commencement of recurring U.S. revenues alongside subscription income. 

With Northeast Georgia Health System and Cone Health also executing commercial agreements, all three of our U.S. foundation partners have now converted to commercial customers, establishing a strong platform for expansion in 2026.

Last month, Wilson Asset Management listed this ASX healthcare stock as a buying opportunity.

The recent dip in share price could present an opportunity for prospective investors. 

4DMedical

4DMedical is a medical technology company working in the field of respiratory imaging and ventilation analysis in the treatment of lung and respiratory diseases.

Its share price is up almost 500% in the last year. 

However, it has shed almost 40% in the last 3 weeks of trading. 

This includes a drop of more than 6% yesterday, closing at $3.15. 

Estimates from brokers indicate this could be an attractive entry point for investors. 

A recent share price target from Bell Potter of $4.50 indicates a potential upside of 42.86%. 

The broker said 4DX has never been better positioned to make major inroads into the US market. 

The post Two booming ASX healthcare stocks investors should be buying the dip on appeared first on The Motley Fool Australia.